Rising awareness about bone health and technological advancements in diagnosis are expected to drive market expansion in the near future at a CAGR of 5.90% from 2024 to 2032.

Market Research Future (MRFR) has published a research report on the “Global Postmenopausal Osteoporosis Market” that contains information from 2019 to 2032. The Postmenopausal Osteoporosis market is estimated to register a CAGR of 5.90% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Postmenopausal Osteoporosis market— Pfizer Inc., Amgen, F. Hoffmann-La Roche Ltd, Novartis AG, Chugai Pharma China Co., Ltd., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Paras Biopharmaceuticals Finland Oy, Ligand Pharmaceuticals Incorporated, and Eli Lilly and Company.

Market Highlights

The global Postmenopausal Osteoporosis market has registered a CAGR of 5.90% during the forecast period and is estimated to reach USD 15.3 billion by 2032.

Technological developments in diagnosis, like bone densitometry (DEXA) scans and genetic testing, are increasing the rate of diagnosis by facilitating better early osteoporosis detection. Additionally, numerous osteoporosis drugs have possible adverse effects, such as gastrointestinal problems or an elevated risk of fractures, which may discourage patients from starting therapy or force them to stop altogether. Furthermore, there is a substantial chance for drug organizations to develop unique treatments focusing on clever pathways engaged with bone metabolism, offering further developed viability and security profiles compared with existing medicines. Moreover, an important obstacle is the underdiagnosis of osteoporosis, which results in a large number of people receiving inadequate or no treatment at all, raising their risk of fractures and related problems.

Segment Analysis

The global Postmenopausal Osteoporosis market has been segmented based on drug class, route of administration, and distribution channel.

Based on the drug class, the market is segmented into bisphosphonates, selective estrogen receptor modulators (SERMs), anabolic class, rank ligand inhibitors, calcium metabolism modifiers, and others. The bisphosphonates segment was attributed to holding the largest market share in 2023. Major clinical recommendations and consensus statements regard bisphosphonates as first-line therapy for postmenopausal osteoporosis. Because of their well-established effectiveness and safety profile, they are frequently given as first therapy for patients who have just received a diagnosis or who are at high risk of fracture.

The global Postmenopausal Osteoporosis market has been segmented based on the route of administration: oral, intravenous, and subcutaneous. In 2023, the oral segment was anticipated to have the highest market share. Because oral drugs have flexible dosage schedules, medical professionals may modify a patient's therapy according to their unique needs, the severity of their ailment, and how well their reaction to treatment is working. This adaptability makes customized medicine methods for postmenopausal osteoporosis care easier.

The global Postmenopausal Osteoporosis market has been segmented based on distribution channels in hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment was anticipated to dominate the market in 2023. Retail pharmacies provide postmenopausal osteoporosis patients with follow-up care and assistance, including medication monitoring, refill reminders, and lifestyle change counseling. Treatment results are improved, and this ongoing assistance fosters patient involvement.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Postmenopausal Osteoporosis Market Research Report

Regional Analysis

Based on region, the global Postmenopausal Osteoporosis market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The European Postmenopausal Osteoporosis market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Postmenopausal Osteoporosis market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Postmenopausal Osteoporosis market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share because of the diverse organization's supervision. For instance, on September 7, 2021, the nonprofit, interdisciplinary North American Menopause Society (NAMS) delivered another approach articulation detailing the association's principles for the treatment of osteoporosis in postmenopausal ladies. The remarks suggest that the hip T-score is a useful objective to guide therapy decisions since the existing data shows a link between the patient's risk of fracture and the bone mineral density assessed during treatment. The statement also describes other treatment strategies for women who are at extremely high risk of fracture, including starting treatment with a bone-building medication and then switching to an anti-remodeling medication, including denosumab and bisphosphonates.

Moreover, the European market has been persistently growing over the forecast period. For instance, the sclerostin inhibitor romosozumab was recommended by the U.K. National Institute for Health and Care Excellence (NICE) on May 25, 2022, as a therapy option for postmenopausal individuals in England and Wales who had a significant osteoporotic fracture during the preceding 24 months. Romosozumab is the primary osteoporosis medicine, but it is declining bone resorption and advanced bone development, making it the main new class of prescription to be made accessible for the condition in almost a decade. More than 20,000 patients in Britain and Wales might be eligible for the prescription, as per its creators, Amgen and UCB.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. The maturing populace, particularly in countries like China and Japan, is a serious area of strength for driving the postmenopausal osteoporosis treatment market in the Asia-Pacific region. Remarkable advancements incorporate the presentation of further developed treatments, more prominent access to clinical services, and developing attention to medical care. Drug firms are also emphasizing customized methodologies to address regionally specific hereditary and way-of-life factors, demonstrating a change in osteoporosis care toward customized medication.

Furthermore, the rest of the world's Postmenopausal Osteoporosis market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's increasing prevalence of osteoporosis, increasing disposable income, cultural shifts, women's health awareness, and adoption of telemedicine and digital health solutions, all of which contribute to the market expansion.

Key Findings of the Study

• The global Postmenopausal Osteoporosis market is expected to reach USD 15.3 billion by 2032, at a CAGR of 5.90% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. Developing business sectors in Asia Pacific, like China, India, and Southeast Asian nations, present huge learning experiences for the drug business. These business sectors have enormous populations, expanding medical care spending and extending access to medical services administrations, driving interest in osteoporosis therapies.


• Based on Drug Class, the Bisphosphonates segment was attributed to holding the largest market in 2023.


• Pfizer Inc., Amgen, F. Hoffmann-La Roche Ltd, Novartis AG, Chugai Pharma China Co., Ltd., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Paras Biopharmaceuticals Finland Oy, Ligand Pharmaceuticals Incorporated, and Eli Lilly and Company are the key market players.